Biomarcadores asociados con la supervivencia y la respuesta terapéutica a la radioembolización con esferas cargadas de itrio-90 en las metástasis hepáticas del carcinoma colorrectal: nuestra experiencia / Biomarkers associated with survival and favourable outcome of radioembolization with yttrium-90 glass microspheres for colon cancer liver metastases: Single centre experience

Objetivo: Analizar la eficacia terapéutica, seguridad y valor pronóstico de diferentes biomarcadores de la radioembolización transarterial con esferas de itrio-90 (TARE) en pacientes con metástasis hepáticas de cáncer colorrectal. Material y métodos: Estudio prospectivo que incluye los pacientes con metástasis hepáticas de cancer colorrectal tratados con TARE entre noviembre de 2015 y junio de 2020. Se analizó la respuesta terapéutica (3 y 6 meses, criterios RECIST v1.1) mediante el cálculo de las tasas de respuesta tumoral objetiva (ORR) y de control de la enfermedad (DCR), así como la asociación de los biomarcadores con la respuesta terapéutica y la supervivencia global (SG) y libre de progresión (SLP). Resultados: Treinta TARE en 23 pacientes (edad media 61,61±9,13 años; 56,5% varones). La ORR a los 3 meses fue del 16,7% y el DCR del 53,3%. A los 6 meses progresaron el 80% de los pacientes. La ORR y DCR se asociaron con la edad (p=0,047), tratamiento con bevacizumab (p=0,008), hemoglobina (p=0,008), NLR (p=0,040), albúmina (p=0,012) y GPT (p=0,023) previas a la TARE, y la dosis absorbida tumoral estimada>115Gy (p=0,033). La mediana de SG fue de 12 meses (IC 95%: 4,75-19,25 meses) y de SLP 3 meses (IC 95%: 2,41-3,59 meses). La SG se asoció con la cirugía del tumor primario (p=0,019), mutación KRAS (p=0,024), hemoglobina (p=0,009), NLR (p=0,005) y PLR (p=0,042) previos a la TARE. Conclusión: Los biomarcadores con capacidad para predecir el pronóstico y respuesta terapéutica a la TARE incluyen desde parámetros bioquímicos a factores relacionados con la dosimetría tumoral estimada (AU)

Objetivo: To determine the therapeutic effectiveness and safety of transarterial radioembolization (TARE) with Yttrium-90 in patients with colorectal cancer (CRC) liver metastases and to evaluate the prognostic value of different biomarkers. Material and methods: This prospective longitudinal study enrolled consecutive patients with CRC liver metastases treated with TARE between November 2015 and june 2020. The therapeutic response at three and six months (RECIST1.1 criteria) and the relationship of biomarkers with therapeutic response, by calculating objective tumor response rates (ORR) and disease control (DCR), and overall survival (OS) and progression-free (PFS). Results: Thirty TAREs were performed in 23 patients (mean age, 61,61±9,13 years; 56,5% male). At three months, the objective response rate (ORR) was 16,7% and the disease control rate (DCR) 53,3%. At six months, the disease progressed in 80%. The ORR and DCR were significantly associated with age at diagnosis (P=.047), previous bevacizumab treatment (P=.008), pre-TARE haemoglobin (P=.008), NLR (P=.040), pre-TARE albumin (P=.012), pre-TARE ALT (P=.023) and tumour-absorbed dose>115Gy (P=.033). Median overall survival (OS) was 12 months (95% CI, 4.75-19.25 months) and median progression-free survival (PFS) 3 months (95% CI, 2.41-3.59). OS was significantly associated with primary tumour resection (P=.019), KRAS mutation (HR: 5.15; P=.024), pre-TARE haemoglobin (HR: .50; p=.009), pre-TARE NLR (HR: 1.65; P=.005) and PLR (HR: 1.01; P=.042). Conclusion: TARE prognosis and therapeutic response were predicted by different biomarkers, ranging from biochemical parameters to tumour dosimetrics (AU)

Biomarkers associated with survival and favourable outcome of radioembolization with yttrium-90 glass microspheres for colon cancer liver metastases: Single centre experience.

OBJECTIVE: To determine the therapeutic effectiveness and safety of transarterial radioembolization (TARE) with Yttrium-90 in patients with colorectal cancer (CRC) liver metastases and to evaluate the prognostic value of different biomarkers. MATERIAL AND METHODS: This prospective longitudinal study enrolled consecutive patients with CRC liver metastases treated with TARE between November 2015 and june 2020. The therapeutic response at three and six months (RECIST1.1 criteria) and the relationship of biomarkers with therapeutic response, by calculating objective tumor response rates (ORR) and disease control (DCR), and overall survival (OS) and progression-free (PFS). RESULTS: Thirty TAREs were performed in 23 patients (mean age, 61.61 ±â€¯9.13 years; 56.5% male). At three months, the objective response rate (ORR) was 16.7% and the disease control rate (DCR) 53.3%. At six months, the disease progressed in 80%. The ORR and DCR were significantly associated with age at diagnosis (P = 0.047), previous bevacizumab treatment (P = 0.008), pre-TARE haemoglobin (P = 0.008), NLR (P = 0.040), pre-TARE albumin (P = 0.012), pre-TARE ALT (P = 0.023) and tumour-absorbed dose > 115 Gy (P = 0.033). Median overall survival (OS) was 12 months (95% CI, 4.75-19.25 months) and median progression-free survival (PFS) 3 months (95% CI, 2.41-3.59). OS was significantly associated with primary tumour resection (P = 0.019), KRAS mutation (HR: 5.15; P = 0.024), pre-TARE haemoglobin (HR: 0.50; p = 0.009), pre-TARE NLR (HR: 1.65; P = 0.005) and PLR (HR: 1.01; P = 0.042). CONCLUSION: TARE prognosis and therapeutic response were predicted by different biomarkers, ranging from biochemical parameters to tumour dosimetrics.

Biomarkers associated with survival and favourable outcome of radioembolization with yttrium-90 glass microspheres for colon cancer liver metastases: Single centre experience. / Biomarcadores asociados con la supervivencia y la respuesta terapéutica a la radioembolización con esferas cargadas de itrio-90 en las metástasis hepáticas del carcinoma colorrectal: nuestra experiencia.

OBJETIVE: To determine the therapeutic effectiveness and safety of transarterial radioembolization (TARE) with Yttrium-90 in patients with colorectal cancer (CRC) liver metastases and to evaluate the prognostic value of different biomarkers. MATERIAL AND METHODS: This prospective longitudinal study enrolled consecutive patients with CRC liver metastases treated with TARE between November 2015 and june 2020. The therapeutic response at three and six months (RECIST1.1 criteria) and the relationship of biomarkers with therapeutic response, by calculating objective tumor response rates (ORR) and disease control (DCR), and overall survival (OS) and progression-free (PFS). RESULTS: Thirty TAREs were performed in 23 patients (mean age, 61,61±9,13 years; 56,5% male). At three months, the objective response rate (ORR) was 16,7% and the disease control rate (DCR) 53,3%. At six months, the disease progressed in 80%. The ORR and DCR were significantly associated with age at diagnosis (P=.047), previous bevacizumab treatment (P=.008), pre-TARE haemoglobin (P=.008), NLR (P=.040), pre-TARE albumin (P=.012), pre-TARE ALT (P=.023) and tumour-absorbed dose>115Gy (P=.033). Median overall survival (OS) was 12 months (95% CI, 4.75-19.25 months) and median progression-free survival (PFS) 3 months (95% CI, 2.41-3.59). OS was significantly associated with primary tumour resection (P=.019), KRAS mutation (HR: 5.15; P=.024), pre-TARE haemoglobin (HR: .50; p=.009), pre-TARE NLR (HR: 1.65; P=.005) and PLR (HR: 1.01; P=.042). CONCLUSION: TARE prognosis and therapeutic response were predicted by different biomarkers, ranging from biochemical parameters to tumour dosimetrics.

Desarrollo de un mapa de riesgos para la tomografía por emisión de positrones / Development of a positron emission tomography risks map

La seguridad del paciente es un componente esencial de la calidad asistencial, especialmente cuando la complejidad de la asistencia ha alcanzado niveles extremos. En la actualidad, conseguir esta seguridad se considera una estrategia básica del sistema nacional de salud. Los servicios de Medicina Nuclear muestran unas particularidades que los hacen especiales en materia de seguridad del paciente, con situaciones que se salen de la práctica asistencial común de los servicios del resto del marco hospitalario. Estas particularidades vienen definidas por el hecho de utilizar en la actividad diaria radiaciones ionizantes, tanto encapsuladas como no encapsuladas. Además, y concretamente en el caso de la tomografía por emisión de positrones (PET), el hecho de realizar la exploración implica de modo indispensable la coordinación de numerosos grupos de profesionales, tanto de la propia unidad de gestión clínica como de otros servicios del hospital (incluso de empresas ajenas al propio hospital y al propio sistema sanitario público). El objetivo del presente trabajo ha sido identificar los riesgos a los que puede exponerse un paciente que va a ser explorado mediante PET en un servicio de Medicina Nuclear y elaborar el mapa de riesgos para el proceso PET. La metodología empleada se enmarca genéricamente en la propuesta por el Ministerio de Sanidad (2007) y su concreción práctica (dada la escasa literatura disponible en Medicina Nuclear) sigue en lo posible lo desarrollado en áreas asistenciales afines (radiodiagnóstico y radioterapia). Para ello, se constituyó un equipo multidisciplinar de profesionales directamente relacionados con el proceso PET, se utilizó la metodología análisis modal de fallos y efectos con la intención de identificar los posibles fallos, sus causas y los potenciales eventos adversos que provocan cada uno de los fallos. Como paso final, se creó el mapa de riesgos, ubicando en cada etapa del proceso los fallos previamente identificados. El presente trabajo expone el proceso PET, el cual ha permitido describir los riesgos que puede correr un paciente cuando es requerido para realizarse una exploración PET, así como los eventos adversos derivados de ellos. Todo ello ha quedado plasmado en un mapa de riesgos del proceso PET

Patient safety is an essential component of quality of care, especially when the complexity of care has reached extreme levels. Currently achieving this safety is considered a basic strategy of the National Health System. Nuclear Medicine departments have certain peculiarities that make them special in terms of patient safety, with situations that go beyond the common healthcare practice of other departments. Namely, that both encapsulated and non-encapsulated ionizing radiation is used in daily practice, and numerous groups of professionals must be coordinated to undertake positron emission tomography (PET) specifically, from the clinical management unit itself, and from other departments of the hospital (as well as companies outside the hospital itself and the Public Health System). The objective of this paper was to identify the risks to which a patient who is to be explored through PET can be exposed in a Nuclear Medicine department and draw up a risk map for the PET process. The methodology used is part of the proposal of the Ministry of Health (2007), and its practical implementation (given the limited literature available on Nuclear Medicine), follows as far as possible that of related care areas (radiodiagnosis and radiotherapy). For this purpose, a multidisciplinary team of professionals directly related to the PET process was created, using the modal analysis of faults and effects methodology to identify possible failures, their causes and the potential adverse events causing each. As a final step, a risk map was created, locating the previously identified faults at each stage of the process. This paper exposes the PET process, and describes the risks that patients might run when a PET scan is required, as well as the adverse events deriving from it. All this is shown in a risk map of the PET process

Development of a positron emission tomography risks map. / Desarrollo de un mapa de riesgos para la tomografía por emisión de positrones.

Patient safety is an essential component of quality of care, especially when the complexity of care has reached extreme levels. Currently achieving this safety is considered a basic strategy of the National Health System. Nuclear Medicine departments have certain peculiarities that make them special in terms of patient safety, with situations that go beyond the common healthcare practice of other departments. Namely, that both encapsulated and non-encapsulated ionizing radiation is used in daily practice, and numerous groups of professionals must be coordinated to undertake positron emission tomography (PET) specifically, from the clinical management unit itself, and from other departments of the hospital (as well as companies outside the hospital itself and the Public Health System). The objective of this paper was to identify the risks to which a patient who is to be explored through PET can be exposed in a Nuclear Medicine department and draw up a risk map for the PET process. The methodology used is part of the proposal of the Ministry of Health (2007), and its practical implementation (given the limited literature available on Nuclear Medicine), follows as far as possible that of related care areas (radiodiagnosis and radiotherapy). For this purpose, a multidisciplinary team of professionals directly related to the PET process was created, using the modal analysis of faults and effects methodology to identify possible failures, their causes and the potential adverse events causing each. As a final step, a risk map was created, locating the previously identified faults at each stage of the process. This paper exposes the PET process, and describes the risks that patients might run when a PET scan is required, as well as the adverse events deriving from it. All this is shown in a risk map of the PET process.

PET amiloide en enfermedades neurodegenerativas que cursan con demencia / Amyloid PET in neurodegenerative diseases with dementia

La enfermedad de Alzheimer (EA) es una enfermedad neurodegenerativa que se caracteriza por un deterioro cognitivo progresivo y pérdida de memoria, siendo la causa más común de demencia. Los hallazgos anatomopatológicos de la EA son los depósitos de Aβ amiloide y proteína Tau, que producen disfunción sináptica y muerte neuronal. La PET amiloide es una técnica útil, disponible y no invasiva que nos proporciona información in vivo del depósito amiloide. En las últimas revisiones de los criterios diagnósticos de la EA se definen e incorporan los biomarcadores, que se clasifican en biomarcadores fisiopatológicos o de diagnóstico (aumento de la retención fibrilar amiloide observada por PET o disminución del péptido Aβ1-42 y elevación de las proteínas T-Tau y F-Tau en el LCR) y biomarcadores de neurodegeneración o topográficos (disminución del metabolismo temporoparietal en la PET-FDG y atrofia temporal medial en la RM). Recientemente se han creado unas recomendaciones específicas para la correcta utilización de los biomarcadores, donde se incluye la PET amiloide: deterioro cognitivo persistente/progresivo, deterioro cognitivo atípico, deterioro cognitivo de inicio precoz y diagnóstico diferencial entre EA y otras enfermedades neurodegenerativas que cursan con demencia. Nuevos estudios de investigación y ensayos clínicos están utilizando la PET amiloide en la evaluación y el desarrollo de nuevas terapias para la EA, así como para el estudio de otras enfermedades neurodegenerativas que cursan con demencia. En este trabajo revisamos algunos conceptos generales y profundizamos en el uso de esta nueva técnica y su relación con las enfermedades neurodegenerativas y el resto de las técnicas diagnósticas

Alzheimer's disease (AD) is a neurodegenerative condition characterized by progressive cognitive decline and memory loss, and is the most common form of dementia. Amyloid plaques with neurofibrillary tangles are a neuropathological hallmark of AD that produces synaptic dysfunction and culminates later in neuronal loss. Amyloid PET is a useful, available and non-invasive technique that provides in vivo information about the cortical amyloid burden. In the latest revised criteria for the diagnosis of AD biomarkers were defined and integrated: pathological and diagnostic biomarkers (increased retention on fibrillar amyloid PET or decreased Aβ1-42 and increased T-Tau or P-Tau in CSF) and neurodegeneration or topographical biomarkers (temporoparietal hypometabolism on 18F-FDG PET and temporal atrophy on MRI). Recently specific recommendations have been created as a consensus statement on the appropriate use of the imaging biomarkers, including amyloid PET: early-onset cognitive impairment/dementia, atypical forms of AD, mild cognitive impairment with early age of onset, and to differentiate between AD and other neurodegenerative diseases that occur with dementia. Amyloid PET is also contributing to the development of new therapies for AD, as well as in research studies for the study of other neurodegenerative diseases that occur with dementia where the deposition of Aβ amyloid is involved in its pathogenesis. In this paper, we review some general concepts and study the use of amyloid PET in depth and its relationship with neurodegenerative diseases and other diagnostic techniques

Amyloid PET in neurodegenerative diseases with dementia. / PET amiloide en enfermedades neurodegenerativas que cursan con demencia.

Alzheimer's disease (AD) is a neurodegenerative condition characterized by progressive cognitive decline and memory loss, and is the most common form of dementia. Amyloid plaques with neurofibrillary tangles are a neuropathological hallmark of AD that produces synaptic dysfunction and culminates later in neuronal loss. Amyloid PET is a useful, available and non-invasive technique that provides in vivo information about the cortical amyloid burden. In the latest revised criteria for the diagnosis of AD biomarkers were defined and integrated: pathological and diagnostic biomarkers (increased retention on fibrillar amyloid PET or decreased Aß1-42 and increased T-Tau or P-Tau in CSF) and neurodegeneration or topographical biomarkers (temporoparietal hypometabolism on 18F-FDG PET and temporal atrophy on MRI). Recently specific recommendations have been created as a consensus statement on the appropriate use of the imaging biomarkers, including amyloid PET: early-onset cognitive impairment/dementia, atypical forms of AD, mild cognitive impairment with early age of onset, and to differentiate between AD and other neurodegenerative diseases that occur with dementia. Amyloid PET is also contributing to the development of new therapies for AD, as well as in research studies for the study of other neurodegenerative diseases that occur with dementia where the deposition of Aß amyloid is involved in its pathogenesis. In this paper, we review some general concepts and study the use of amyloid PET in depth and its relationship with neurodegenerative diseases and other diagnostic techniques.

Nuevos tiempos para la neuroimagen de Medicina Nuclear en España: ¿de dónde partimos? / A new era for Nuclear Medicine neuroimaging in Spain: Where do we start from in Spain?

Objetivo. conocer la situación de los estudios de neuroimagen de Medicina Nuclear que se realizaron en España en el año 2013 y primer trimestre del 2014, con el fin de definir las actividades del grupo de trabajo de Neuroimagen de la Sociedad Española de Medicina Nuclear e Imagen Molecular (SEMNIM). Material y métodos. Se diseñó un cuestionario de 14 preguntas dividido en 3 partes: características de los servicios (equipamiento y profesionales involucrados), tipo de exploraciones e indicaciones clínicas y métodos de evaluación. El cuestionario se remitió a los 166 servicios de Medicina Nuclear que figuraban en la secretaría de la Sociedad Española de Medicina Nuclear e Imagen Molecular. Resultados. Respondieron a la encuesta un total de 54 centros distribuidos entre todas las comunidades autónomas. La mayoría de los centros realizaron entre 300 y 800 exploraciones de neuroimagen al año, representando más de 25 exploraciones al mes. La media de equipos por servicio era de 3, teniendo la mitad de ellos equipos PET/TC y SPECT/TC. Las exploraciones realizadas con más frecuencia son la SPECT cerebral con 123I-FP-CIT, seguida de la SPECT cerebral de perfusión y de la PET con 18F-FDG, siendo las indicaciones clínicas más frecuentes los estudios de deterioro cognitivo seguidos por los de trastornos del movimiento. Para la evaluación de las pruebas la mayoría de los centros utilizaron únicamente la valoración visual, en la valoración cuantitativa la cuantificación por regiones de interés fue la más utilizada. Conclusiones. Los resultados reflejan cuál fue la actividad clínica del año 2013 y primer trimestre del 2014, siendo las indicaciones principales los estudios de deterioro cognitivo y trastorno del movimiento. La variabilidad en la evaluación de los estudios PET y la colaboración con los especialistas clínicos que demandan las exploraciones de neuroimagen de Medicina Nuclear son algunos de los retos que debemos afrontar en los próximos años (AU)

Objective. To determine the status of neuroimaging studies of Nuclear Medicine in Spain during 2013 and first quarter of 2014, in order to define the activities of the neuroimaging group of the Spanish Society of Nuclear Medicine and Molecular Imaging (SEMNIM). Material and methods. A questionnaire of 14 questions was designed, divided into 3 parts: characteristics of the departments (equipment and professionals involved); type of scans and clinical indications; and evaluation methods. The questionnaire was sent to 166 Nuclear Medicine departments. Results. A total of 54 departments distributed among all regions completed the questionnaire. Most departments performed between 300 and 800 neuroimaging examinations per year, representing more than 25 scans per month. The average pieces of equipment were three; half of the departments had a PET/CT scanner and SPECT/CT equipment. Scans performed more frequently were brain SPECT with 123I-FP-CIT, followed by brain perfusion SPECT and PET with 18F-FDG. The most frequent clinical indications were cognitive impairment followed by movement disorders. For evaluation of the images most sites used only visual assessment, and for the quantitative assessment the most used was quantification by region of interest. Conclusions. These results reflect the clinical activity of 2013 and first quarter of 2014. The main indications of the studies were cognitive impairment and movement disorders. Variability in the evaluation of the studies is among the challenges that will be faced in the coming years (AU)

A new era for Nuclear Medicine neuroimaging in Spain: Where do we start from in Spain? / Nuevos tiempos para la neuroimagen de Medicina Nuclear en España: ¿de dónde partimos?

OBJECTIVE: To determine the status of neuroimaging studies of Nuclear Medicine in Spain during 2013 and first quarter of 2014, in order to define the activities of the neuroimaging group of the Spanish Society of Nuclear Medicine and Molecular Imaging (SEMNIM). MATERIAL AND METHODS: A questionnaire of 14 questions was designed, divided into 3 parts: characteristics of the departments (equipment and professionals involved); type of scans and clinical indications; and evaluation methods. The questionnaire was sent to 166 Nuclear Medicine departments. RESULTS: A total of 54 departments distributed among all regions completed the questionnaire. Most departments performed between 300 and 800 neuroimaging examinations per year, representing more than 25 scans per month. The average pieces of equipment were three; half of the departments had a PET/CT scanner and SPECT/CT equipment. Scans performed more frequently were brain SPECT with 123I-FP-CIT, followed by brain perfusion SPECT and PET with 18F-FDG. The most frequent clinical indications were cognitive impairment followed by movement disorders. For evaluation of the images most sites used only visual assessment, and for the quantitative assessment the most used was quantification by region of interest. CONCLUSIONS: These results reflect the clinical activity of 2013 and first quarter of 2014. The main indications of the studies were cognitive impairment and movement disorders. Variability in the evaluation of the studies is among the challenges that will be faced in the coming years.

Hibernoma as an incidental finding on 18F-FDG-PET/CT in lymphoma patient follow-up / Hibernoma como hallazgo incidental en la 18F-FDG-PET/TC en paciente en seguimiento por linfoma

No disponible

Papel de la tomografía por emisión de positrones/tomografía computarizada con análogos radiomarcados de colina en el cáncer de próstata / The role of positron emission tomography/computed tomography imaging with radiolabeled choline analogues in prostate cancer

Introducción: El cáncer de próstata es el tumor maligno sólido más frecuente en los países occidentales. La tomografía por emisión de positrones/tomografía computarizada con análogos radiomarcados de colina es una herramienta útil en la re-estadificación de pacientes con aumento del antígeno prostático específico después de tratamiento radical -donde las técnicas de imagen convencional tienen limitaciones importantes- así como en un seleccionado grupo de pacientes en la valoración inicial de esta neoplasia. Esta situación nos lleva a plantear una revisión de la literatura donde se evalúe la utilidad de esta exploración en la toma de decisiones diagnóstico-terapéuticas en el cáncer de próstata. Evidencia de adquisición: Realizamos una búsqueda bibliográfica a través de la base de datos Medline (vía Pubmed) utilizando los términos Prostate cancer y Choline-PET/CT a los que añadimos los términos Biochemical failurey/o Staging y/o PSA kinetics. Así mismo, seleccionamos los trabajos en lengua inglesa y española e incluimos artículos originales, revisiones, revisiones sistemáticas, metaanálisis y guías de práctica clínica. Conclusiones: De acuerdo con los datos disponibles los análogos radiomarcados de colina desempeñan un papel importante en el manejo del cáncer de próstata, especialmente en la recurrencia bioquímica, donde la exactitud de la técnica se correlaciona bien con el valor del antígeno prostático específico y su cinética. Aunque esta técnica se perfila como una modalidad diagnóstica de aplicación en la planificación del tratamiento del cáncer de próstata, aún no se han realizado recomendaciones finales sobre su uso

Introduction: prostate cancer is the most frequent solid malignant tumor in Western Countries. Positron emission tomography/x-ray computed tomography imaging with radiolabeled choline analogues is a useful tool for restaging prostate cancer in patients with rising prostate-specific antigen after radical treatment (in whom conventional imaging techniques have important limitations) as well as in the initial assessment of a selected group of prostate cancer patients. For this reason a literature review is necessary in order to evaluate the usefulness of this imaging test for the diagnosis and treatment of prostate cancer. Evidence acquisition: a MEDLINE (PubMed way) literature search was performed using the search parameters: «Prostate cancer» and «Choline-PET/CT». Other search terms were «Biochemical failure» and/or «Staging» and/or «PSA kinetics». English and Spanish papers were selected; original articles, reviews, systematic reviews and clinical guidelines were included. Conclusions: according to available data, radiolabeled choline analogues plays an important role in the management of prostate cancer, especially in biochemical relapse because technique accuracy is properly correlated with prostate-specific antigen values and kinetics. Although is an emerging diagnostic technique useful in treatment planning of prostate cancer, final recommendations have not been submitted

SPECT-perfusión cerebral regional "off-on": a propósito de un caso de catatonia / Regional cerebral blood flow-SPECT "OFF-ON": a case report of catatonia

Se expone el caso de una paciente con distimia de larga evolución y episodios depresivos graves que precisaron hospitalización. En el último de ellos, que se describe a continuación, se asoció sintomatología de tipo catatoniforme junto a rasgos sugerentes de deterioro cognitivo. La ausencia de una clara respuesta psicofarmacológica inicial junto a la severidad clínica de la paciente plantearon la posibilidad de utilizar terapia electroconvulsiva (TEC). Para descartar una posible enfermedad de Alzheimer (EA) concomitante se exploró mediante tomografía de perfusión cerebral regional (SPECT-PCr) observándose una marcada hipocaptación neocortical sin un claro patrón de deterioro primario sobreañadido. El inicio de una mejoría clínica gradual y la objetivación de una reperfusión cerebral global, corroborada en una segunda SPECT-PCr a 2 semanas de su ingreso, desestimaron el empleo de TEC sugiriendo la pertinencia de adoptar una actitud expectante (AU)

We report the case of a patient with a long history of dysthymia and major depressive episodes requiring repeated hospitalization. We describe the most recent episode, associated with catatonia symptomatology and features suggestive of cognitive impairment. The absence of a clear initial psychopharmacological response alongside the clinical severity made the patient a potential candidate for electroconvulsive therapy (ECT). A regional cerebral blood flow SPECT (SPECT-rCBF), performed to rule out concomitant Alzheimer disease (AD), revealed a markedly decreased neocortical uptake, with no definitive pattern of concomitant primary cognitive impairment. Because a gradual clinical improvement was observed in the patient, with evidence of enhanced cerebral reperfusion in a second SPECT-rCBF study at two weeks after admission, the application of ECT was discounted and an expectant attitude was adopted (AU)

Utilidad de la pet/tac en la estadificación mediastínica del cáncer pulmonar de células no pequeñas en estadio iii (N2) / Usefulness of ct and pet scans in mediastinal stagingof stage iii (n2) non-small-cell lung cancer

OBJETIVO: Evaluar la validez diagnóstica de la tomografía por emisión de positrones con 18F-fluoro-2-deoxi-D-glucosa y la tomografía computerizada (PET/TAC), como de las maniobras quirúrgicas de estadificación mediastínica (N2) en pacientes con carcinoma broncogénico no microcítico, analizando ambos resultados. MATERIAL Y MÉTODOS: Estudio prospectivo de pacientes con diagnóstico o alta sospecha de carcinoma broncogénico, y posible afectación N2 mediante TAC con contraste y PET/TAC. Se analizaron por pacientes y grupos adenopáticos, confirmándose mediante análisis histopatológico. Se calcularon sensibilidad, especificidad, valor predictivo positivo y valor predictivo negativo del estudio PET/TAC así como de las maniobras quirúrgicas. RESULTADOS: Se incluyeron 67 pacientes clasificados como N2 mediante TAC con contraste. El PET/TAC clasificó a 63 pacientes como N2. Se encontraron discrepancias en 7 pacientes, 6 como falsos positivos y 1 como falso negativo. Las maniobras invasivas de estadificación analizaron 123 estaciones ganglionares, obteniendo resultado histopatológico en 98 de ellas. La PET/TAC clasificó como positivas 78, 10 falsos positivos y 10 falsos negativos. Para las maniobras invasivas se obtuvieron un total de 97 estaciones ganglionares, 75 positivas, 2 falsos positivos y 5 falsos negativos. CONCLUSIONES: El estudio PET/TAC presenta buena sensibilidad, más una especificidad discreta, en la correcta clasificación de pacientes N2 debido a limitaciones clínico-quirúrgicas. Las técnicas para la comprobación histológica de los hallazgos obtenidos en imagen, presentaron una alta validez diagnóstica. Los resultados delimitan tres subgrupos clínicos de utilidad, en los que cumpliendo unos requisitos radiológicos y clínicos, la cirugía de estadificación puede reservarse, seleccionando los pacientes y evitando la morbimortalidad de la cirugía

OBJECTIVE: To assess the diagnostic validity of FDG-PET, PET-CT, and surgical mediastinal staging (N2) in patients with non-small-cell lung cancer (NSCLC), comparing the outcomes obtained with such diagnostic procedures. MATERIAL AND METHODS: Prospective study of patients with diagnosis of bronchogenic carcinoma and suspected N2 disease by CT and PET-CT. Sensitivity, specificity, positive predictive value, and negative predictive value were calculated and compared among each diagnostic procedure. The analysis was performed both for patients and for lymph node stations. RESULTS: 67 patients with N2 disease by CT were included in disease by CT were included in the analysis. PET-CT identified 63 patients as being N2. Dis-crepancies were observed in 7 patients: 6 false positive, and 1 false negative. Invasive surgical mediastinal staging analyzed 123 lymph node stations, achieving the pathological diagnosis in 98. PET-CT identified positive 78 lymph nodes, 10 false po-sitive and 10 false negative. For invasive procedures, 97 lymph node stations were obtained, 75 positive, 2 false positive, and 5 false negative. CONCLUSIONS: PET-CT has a high sensitivity but only a modest specificity for the correct N2 staging of patients with NSCLC. Diagnostic methods of pathological confirmation of findings observed in imaging procedures, presented a high diagnostic validity. Our results delineate three clinical subgroups of pa-tients in that invasive procedures for mediastinal staging could be reserved, avoiding surgical morbidity and mortality

[Regional cerebral blood flow-SPECT "OFF-ON": a case report of catatonia]. / SPECT-perfusión cerebral regional «off-on¼: a propósito de un caso de catatonia.

We report the case of a patient with a long history of dysthymia and major depressive episodes requiring repeated hospitalization. We describe the most recent episode, associated with catatonia symptomatology and features suggestive of cognitive impairment. The absence of a clear initial psychopharmacological response alongside the clinical severity made the patient a potential candidate for electroconvulsive therapy (ECT). A regional cerebral blood flow SPECT (SPECT-rCBF), performed to rule out concomitant Alzheimer disease (AD), revealed a markedly decreased neocortical uptake, with no definitive pattern of concomitant primary cognitive impairment. Because a gradual clinical improvement was observed in the patient, with evidence of enhanced cerebral reperfusion in a second SPECT-rCBF study at two weeks after admission, the application of ECT was discounted and an expectant attitude was adopted.

The role of positron emission tomography/computed tomography imaging with radiolabeled choline analogues in prostate cancer.

INTRODUCTION: prostate cancer is the most frequent solid malignant tumor in Western Countries. Positron emission tomography/x-ray computed tomography imaging with radiolabeled choline analogues is a useful tool for restaging prostate cancer in patients with rising prostate-specific antigen after radical treatment (in whom conventional imaging techniques have important limitations) as well as in the initial assessment of a selected group of prostate cancer patients. For this reason a literature review is necessary in order to evaluate the usefulness of this imaging test for the diagnosis and treatment of prostate cancer. EVIDENCE ACQUISITION: a MEDLINE (PubMed way) literature search was performed using the search parameters: «Prostate cancer¼ and «Choline-PET/CT¼. Other search terms were «Biochemical failure¼ and/or «Staging¼ and/or «PSA kinetics¼. English and Spanish papers were selected; original articles, reviews, systematic reviews and clinical guidelines were included. CONCLUSIONS: according to available data, radiolabeled choline analogues plays an important role in the management of prostate cancer, especially in biochemical relapse because technique accuracy is properly correlated with prostate-specific antigen values and kinetics. Although is an emerging diagnostic technique useful in treatment planning of prostate cancer, final recommendations have not been submitted.

Parametrization of textural patterns in 123I-ioflupane imaging for the automatic detection of Parkinsonism.

PURPOSE: A novel approach to a computer aided diagnosis system for the Parkinson's disease is proposed. This tool is intended as a supporting tool for physicians, based on fully automated methods that lead to the classification of (123)I-ioflupane SPECT images. METHODS: (123)I-ioflupane images from three different databases are used to train the system. The images are intensity and spatially normalized, then subimages are extracted and a 3D gray-level co-occurrence matrix is computed over these subimages, allowing the characterization of the texture using Haralick texture features. Finally, different discrimination estimation methods are used to select a feature vector that can be used to train and test the classifier. RESULTS: Using the leave-one-out cross-validation technique over these three databases, the system achieves results up to a 97.4% of accuracy, and 99.1% of sensitivity, with positive likelihood ratios over 27. CONCLUSIONS: The system presents a robust feature extraction method that helps physicians in the diagnosis task by providing objective, operator-independent textural information about (123)I-ioflupane images, commonly used in the diagnosis of the Parkinson's disease. Textural features computation has been optimized by using a subimage selection algorithm, and the discrimination estimation methods used here makes the system feature-independent, allowing us to extend it to other databases and diseases.

Tomografía por emisión de positrones con 18F-fluorodesoxiglucosa en la evaluación preoperatoria de lesiones de vesícula biliar sospechosas de malignidad. Utilidad diagnóstica e impacto clínico / fgfg

Introducción. El cáncer de vesícula (CV) es una neoplasia de mal pronóstico en la que el empleo de la tomografía por emisión de positrones (PET) con 18F-fluorodesoxigluosa (FDG) como herramienta diagnóstica puede ser útil, aunque su papel no está bien definido. Diseño/metodología. Cohorte prospectiva de pacientes con lesión radiológica vesicular sospechosa de malignidad en estudio de diagnóstico y estadificación prequirúrgico mediante PET-FDG en equipos convencionales (PET) y equipos multimodalidad (PET-TAC). Estimación de validez diagnóstica contrastando los resultados de ambos procedimientos con el estudio histopatológico y/o la evolución clínica de los pacientes. Análisis del impacto clínico derivado de su implantación en el diagnóstico del CV. Resultados. Se reclutaron 42 pacientes, 22 con resultado histológico de malignidad y 20 de benignidad. La precisión diagnóstica global fue del 83,33% para el diagnóstico oncológico de la lesión primaria, del 88,89% para la afectación ganglionar y del 85,1% para la afectación metastásica. El SUVmáx medio de las lesiones vesiculares malignas fue 6,14±2,89. La curva ROC mostró un punto de corte de SUVmáx: 3,65 para malignidad. La validez diagnóstica de la PET (n=21) fue discretamente inferior que la de la PET-TAC (n=21). La realización de la PET-FDG modificó la actitud terapéutica en el 14,8%, al encontrar enfermedad diseminada no sospechada. Comentarios. La PET-FDG diagnostica con precisión la malignidad o benignidad de una lesión vesicular sospechosa, añadiendo la capacidad de identificar enfermedad metastásica no sospechada. La PET-TAC mejora la precisión diagnóstica de la PET por la complementariedad metabólico-estructural de su información. El SUVmáx tiene un valor complementario al análisis visual(AU)

gfg(AU)

Efficient mining of association rules for the early diagnosis of Alzheimer's disease.

In this paper, a novel technique based on association rules (ARs) is presented in order to find relations among activated brain areas in single photon emission computed tomography (SPECT) imaging. In this sense, the aim of this work is to discover associations among attributes which characterize the perfusion patterns of normal subjects and to make use of them for the early diagnosis of Alzheimer's disease (AD). Firstly, voxel-as-feature-based activation estimation methods are used to find the tridimensional activated brain regions of interest (ROIs) for each patient. These ROIs serve as input to secondly mine ARs with a minimum support and confidence among activation blocks by using a set of controls. In this context, support and confidence measures are related to the proportion of functional areas which are singularly and mutually activated across the brain. Finally, we perform image classification by comparing the number of ARs verified by each subject under test to a given threshold that depends on the number of previously mined rules. Several classification experiments were carried out in order to evaluate the proposed methods using a SPECT database that consists of 41 controls (NOR) and 56 AD patients labeled by trained physicians. The proposed methods were validated by means of the leave-one-out cross validation strategy, yielding up to 94.87% classification accuracy, thus outperforming recent developed methods for computer aided diagnosis of AD.

Utilidad de la PET/TAC en la estadificación mediastínica del cáncer de pulmón de células no pequeñas en estadio III (N2) / Utility of PET/CT for mediastinal staging of non-small cell lung cancer in stage III (N2)

Objetivo. Evaluar la validez diagnóstica de la tomografía por emisión de positrones con 18F-fluoro-2-deoxi-D-glucosa y la tomografía computarizada (PET/TAC) en la estadificación ganglionar mediastínica (N2) en pacientes con cáncer de pulmón de células no pequeñas (CPCNP) y analizar el papel de la estadificación mediante pruebas invasivas para la verificación de los hallazgos de la tomografía por emisión de positrones (PET)/tomografía computerizada (TAC). Material y métodos. Estudio retrospectivo incluyendo a pacientes con diagnóstico histopatológico de CPCNP, estadificados como N2 mediante TAC+C y estudiados con PET/TAC. Se confirmaron mediante análisis histopatológico de la pieza quirúrgica cuando se dispuso o por consenso iconográfico en el comité de tumores torácicos. Se ha calculado la sensibilidad, especificidad, valor predictivo positivo y valor predictivo negativo del estudio PET/TAC en la correcta clasificación de los pacientes N2. Resultados. Se incluyeron 34 pacientes clasificados como N2 mediante TAC+C. El PET/TAC clasificó a 30 pacientes como estadio N2. Se encontraron discrepancias en 4 pacientes, dos clasificados como N1 y dos como N0. Los resultados fueron confirmados histológicamente en 20 pacientes. El estudio PET/TAC no mostró falsos positivos. La sensibilidad fue del 94,7%, la especificidad y el valor predictivo positivo fue del 100% y el valor predictivo negativo del 50%. Conclusiones. El estudio PET/TAC presenta una alta sensibilidad y valor predictivo positivo en la correcta clasificación de pacientes con afectación ganglionar mediastínica (N2). Nuestros resultados sugieren que en pacientes con cáncer de pulmón potencialmente resecable, candidatos a tratamiento con quimioterapia neoadyuvante, la mediastinoscopia podría reservarse para la re-estadificación(AU)

Purpose. To evaluate the accuracy of integrated positron emission tomography with 18F-fluoro-2-deoxy-D-glucose (FDG) and computed tomography (PET/CT) in mediastinal lymph node staging in patients with potentially operable (N2) non-small cell lung cancer (NSCLC) and to ascertain the role of invasive staging in verifying positron emission tomography (PET)/computed tomography (CT) results. Material and methods. A retrospective study of consecutive patients with pathologically-proven NSCLC and N2 staging by enhanced CT was performed. A PET/CT scan was performed for all the patients. Lymph node staging was pathologically confirmed when it was possible or by consensus in the Thoracic Cancer Committee. Sensitivity, specificity, negative predictive value and positive predictive value of PET/CT in N2 cases were determined. Results. A total of 34 patients with N2 by CT were evaluated. PET/CT showed N2 in 30 patients. Discrepancies were found in four patients, two patients were classified as N1 in PET/CT and two patients as N0. Lymph node staging was pathologically confirmed in 20 patients. No false positives were found in PET/CT study. Sensitivity was 94.7%, specificity and positive predictive values were 100% and negative predictive value was 50%. Conclusions. Our data show that integrated PET/CT provides high sensitivity and positive predictive value in mediastinal nodal staging of NSCLC patients. Therefore, in patients with potentially resectable lung cancer, neoadjuvant chemotherapy candidate, mediastinoscopy could be reserved for restaging after induction therapy(AU)